Agonist

Viatris Announces the Launch of RYZUMVl™ (Phentolamine Ophthalmic Solution) 0.75% in the United States

Retrieved on: 
Monday, April 1, 2024
Glaucoma, Agonist, Rheumatoid arthritis, Phenylephrine, Diabetes, Inflammation, Patient, Ageing, American Optometric Association, Eye injury, American Academy, Mydriasis, United, Viatris, Eye, Parasympatholytic, Uveitis, Lens, Pupil, Tropicamide, FDA, Cataract, Diabetic retinopathy, Food, Pharmaceutical industry

PITTSBURGH, April 1, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced the U.S. commercial launch of RYZUMVI™ (phentolamine ophthalmic solution) 0.75% for the treatment of pharmacologically-induced mydriasis produced by adrenergic agonists (e.g., phenylephrine) or parasympatholytic (e.g., tropicamide) agents in the United States.

Key Points: 
  • PITTSBURGH, April 1, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced the U.S. commercial launch of RYZUMVI™ (phentolamine ophthalmic solution) 0.75% for the treatment of pharmacologically-induced mydriasis produced by adrenergic agonists (e.g., phenylephrine) or parasympatholytic (e.g., tropicamide) agents in the United States.
  • The onset of action of RYZUMVI generally occurs in 30 minutes.
  • In the MIRA-2 trials' placebo group, 34% of patients were still dilated (had not returned to ≤ 0.2 mm of baseline pupil diameter) at 24 hours.
  • To avoid the potential for eye injury or contamination, care should be taken to avoid touching the vial tip to the eye or to any other surface.

Sosei Heptares’ Partner Neurocrine Biosciences Confirms its Plans to Evaluate Two New Muscarinic Agonist Candidates in Phase 1 Clinical Studies

Retrieved on: 
Wednesday, December 6, 2023
Partnership, Trial of the century, Therapy, Pharmacokinetics, Neurocrine Biosciences, Safety, Agonist, Pharmaceutical industry

The studies are designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of NBI-1117569 and NBI-1117567 in healthy adult participants.

Key Points: 
  • The studies are designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of NBI-1117569 and NBI-1117567 in healthy adult participants.
  • NBI-1117569, a muscarinic M4-preferring agonist, and NBI-1117567, a muscarinic M1-preferring agonist are both investigational, oral compounds that may have the potential to treat neurological and neuropsychiatric conditions and were developed utilizing Sosei Heptares' structure-based drug design platform.
  • Neurocrine confirmed a Phase 1 clinical study of NBI-1117569 has started and a Phase 1 study of NBI-1117567 will be initiated in 2024.
  • NBI-1117569 and NBI-1117567 are the third and fourth candidates to advance into clinical trials from the portfolio of selective muscarinic receptor agonists discovered and licensed by Sosei Heptares to Neurocrine in 2021.

Ocuphire Pharma Announces Financial Results for Third Quarter 2023 and Provides Corporate Update

Retrieved on: 
Monday, November 13, 2023
Eye, Food and Drug Administration, Research, Food, Security (finance), Woman, End-user license agreement, American Academy, Patient, Phenylephrine, Presbyopia, FDA, Agonist, Tropicamide, License, Conference, Night vision, OCUP, Met, SPA, Mydriasis, Congress, Diabetic retinopathy, LPC, Pharmaceutical industry, Medical imaging, Cryptocurrency, Viatris, Ophthalmology

FARMINGTON HILLS, Mich., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small-molecule therapies for the treatment of retinal and refractive eye disorders, today announced financial results for the third quarter ended September 30, 2023 and provided a corporate update.

Key Points: 
  • Named as CEO; Conference Call Scheduled for December 5th, 2023, at 10 AM ET
    FARMINGTON HILLS, Mich., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small-molecule therapies for the treatment of retinal and refractive eye disorders, today announced financial results for the third quarter ended September 30, 2023 and provided a corporate update.
  • On August 10, 2023, Ocuphire entered into a common share purchase agreement with Lincoln Park Capital Fund, LLC (“LPC”).
  • Third Quarter ended September 30, 2023, Financial Highlights
    As of September 30, 2023, Ocuphire had cash and cash equivalents of approximately $42.4 million.
  • For further details on Ocuphire’s financial results, refer to the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2023, to be filed with the Securities and Exchange Commission.

Inhibrx Announces Participation in Upcoming Scientific Conferences

Retrieved on: 
Wednesday, October 18, 2023
SAN, Rare, Ewing sarcoma, Agonist, Therapy, Nightclub

SAN DIEGO, Oct. 18, 2023 /PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX), a clinical-stage biopharmaceutical company dedicated to the development of therapeutics for oncology and rare diseases, today announced it will be presenting at the following upcoming scientific conferences:

Key Points: 
  • SAN DIEGO, Oct. 18, 2023 /PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX), a clinical-stage biopharmaceutical company dedicated to the development of therapeutics for oncology and rare diseases, today announced it will be presenting at the following upcoming scientific conferences:
    Title: The Tetravalent Death Receptor 5 Agonist INBRX-109 Combined With Chemotherapy in Ewing Sarcoma: Preliminary Data From A Phase 1 Study
    Location: The Liffey Convention Centre in Dublin, Ireland
    Trial-in-progress poster presentation on Saturday, November 4th, 2023 from 9 AM – 8:30 PM Pacific Standard Time
    Trial-in-progress poster presentation on Saturday, November 4th, 2023 from 9 AM – 8:30 PM Pacific Standard Time
    Location: San Diego Convention Center in San Diego, CA - Hall A
    The posters will be accessible through a link on the investors' section of Inhibrx's website at https://inhibrx.investorroom.com/events-and-presentations upon commencement of each respective presentation.

Viatris and Ocuphire Pharma Announce FDA Approval of RYZUMVl™ (Phentolamine Ophthalmic Solution) 0.75% Eye Drops for the Treatment of Pharmacologically-Induced Mydriasis Produced by Adrenergic Agonists (e.g., Phenylephrine) or Parasympatholytic (e.g., Tro

Retrieved on: 
Wednesday, September 27, 2023
Conjunctivitis, Interim, Dysgeusia, The First Half of My Life, Light, Tropicamide, MBA, Comprehensive, Tropicamide/hydroxyamfetamine, Mydriasis, Pain, Stinger, Patient, Combustion, MIRA, Ageing, Agonist, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Parasympatholytic, Phenylephrine, Pupil, Pharmaceutical industry, Viatris

PITTSBURGH, and FARMINGTON HILLS, Mich., Sept. 27, 2023 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, and Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small-molecule therapies for the treatment of retinal and refractive eye disorders, today announced that the U.S. Food and Drug Administration (FDA) has approved RYZUMVI™ (phentolamine ophthalmic solution) 0.75% for the treatment of pharmacologically-induced mydriasis produced by adrenergic agonists (e.g., phenylephrine) or parasympatholytic (e.g., tropicamide) agents.  RYZUMVl is expected to be commercially available in the U.S. in the first half of 2024.

Key Points: 
  • RYZUMVl is expected to be commercially available in the U.S. in the first half of 2024.
  • Our hope is that by addressing patient dilation barriers, we're empowering eye care professionals to broaden exam availability, leading to enhanced eye health outcomes.
  • Two drops (study eye) or one drop (fellow eye) of RYZUMVI or placebo (vehicle) were administered one hour after instillation of the mydriatic agent.
  • The efficacy of RYZUMVI was similar for all age ranges including pediatric subjects aged 3 to 17 years.

Ocuphire Pharma and Viatris Announce FDA Approval of RYZUMVI™ (Phentolamine Ophthalmic Solution) 0.75% Eye Drops for the Treatment of Pharmacologically-Induced Mydriasis Produced by Adrenergic Agonists (e.g., Phenylephrine) or Parasympatholytic (e.g., Tro

Retrieved on: 
Wednesday, September 27, 2023
Conjunctivitis, Interim, Dysgeusia, Viatris, Light, Hope, Tropicamide, MBA, Tropicamide/hydroxyamfetamine, Mydriasis, OCUP, Pain, Stinger, Patient, Combustion, MIRA, Ageing, Agonist, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Parasympatholytic, Phenylephrine, Pupil, Pharmaceutical industry

RYZUMVI is expected to be commercially available in the U.S. in the first half of 2024.

Key Points: 
  • RYZUMVI is expected to be commercially available in the U.S. in the first half of 2024.
  • Our hope is that by addressing patient dilation barriers, we’re empowering eye care professionals to broaden exam availability, leading to enhanced eye health outcomes.
  • Two drops (study eye) or one drop (fellow eye) of RYZUMVI or placebo (vehicle) were administered one hour after instillation of the mydriatic agent.
  • The efficacy of RYZUMVI was similar for all age ranges including pediatric subjects aged 3 to 17 years.

Revolutionizing Glaucoma Management: Emerging Therapies Projected to Drive Global Market to 2032 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, September 5, 2023
Pharmaceutical, Health, Optical, Ophthalmoscopy, NCX, EU4, OAG, IOP, KOL, Idose, Prevalence, Internet, Epidemiology, Eye, Paratriathlon, USD, Gonioscopy, Compound annual growth rate, ROCK, Patient, Carbonic anhydrase inhibitor, United Kingdom, Growth, Agonist, ACG, Diagnosis, Disease, Pharmaceutical industry, Glaucoma

Emerging Therapies: The glaucoma market is set to experience growth due to the expected entry of emerging therapies, including iDose TR (travoprost intraocular implant), NCX 470, OTX-TIC, and others.

Key Points: 
  • Emerging Therapies: The glaucoma market is set to experience growth due to the expected entry of emerging therapies, including iDose TR (travoprost intraocular implant), NCX 470, OTX-TIC, and others.
  • The report delves into current treatment practices, emerging drugs, market share of individual therapies, and the expected glaucoma market size from 2019 to 2032.
  • Emerging therapies like iDose TR are projected to make substantial contributions to the market by 2032.
  • Emerging Therapies and Drug Pipeline:
    Emerging therapies in the pipeline, such as iDose TR and NCX 470, offer new avenues for glaucoma treatment.

Longboard Pharmaceuticals Reports Full Year 2022 Financial Results and Key Corporate Initiatives

Retrieved on: 
Thursday, March 2, 2023
Biotechnology, Neurology, Health, Pharmaceutical, Clinical Trials, Plasma, Safety, Insurance, Longboard, SLC6A1 epileptic encephalopathy, SAD, Clinical trial, Medication, CNS, DSM-IV codes, Cerebrospinal fluid, Graduate School of Asia-Pacific Studies, Quantitative electroencephalography, PK, PIN, Research, Agonist, Prolactin, Investment, Pharmacology, Trial of the century, PD, Seizure, FINANCIAL, Pharmaceutical industry, Dietary supplement, Health care, Cryptocurrency

Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today provided a corporate update and reported financial results for the full year 2022.

Key Points: 
  • Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today provided a corporate update and reported financial results for the full year 2022.
  • LP352 is the only 5-HT2C receptor agonist being dose optimized for developmental and epileptic encephalopathies (DEEs).
  • FULL YEAR 2022 FINANCIAL RESULTS:
    At December 31, 2022, Longboard’s cash, cash equivalents and short-term investments were approximately $67.6 million.
  • ET to discuss 2022 financial results and provide a corporate update.

The Global Antipsychotic Drugs Market to Register Growth at a CAGR of ~7% by 2027 | DelveInsight

Retrieved on: 
Thursday, February 2, 2023
Pharmacy, Personality disorder, Pfizer, PTSD, Schizoaffective disorder, Safety, Sun Pharma, Lundbeck, Ethics, Cariprazine, Statistics, Anxiety, Alvogen, Bristol Myers Squibb, HDEC, Mental disorder, Bipolar I disorder, Disorder, Depression, Post-traumatic stress disorder, Food, Hallucination, DSM-IV codes, Zydus Lifesciences, Prevalence, USFDA, US Foods, LAS, Mental health, GSK, Laboratory, Government, MDMA, Thought, Addiction, USP, Schizophrenia, Sale, Bipolar disorder, Research, Agonist, Silvio Pettirossi International Airport, COVID-19, Bayer, GSK plc, Cardinal Health, World Health Organization, Drug development, Mania, WHO, Viatris, Conduct disorder, AbbVie, Delusion, Pharmaceutical industry, Medsafe

LAS VEGAS, Feb. 2, 2023 /PRNewswire/ -- DelveInsight's Antipsychotic Drugs Market Insights report provides the current and forecast market analysis, individual leading antipsychotic drugs companies' market shares, challenges, antipsychotic drugs market drivers, barriers, and trends, and key antipsychotic drugs companies in the market.

Key Points: 
  • LAS VEGAS, Feb. 2, 2023 /PRNewswire/ -- DelveInsight's Antipsychotic Drugs Market Insights report provides the current and forecast market analysis, individual leading antipsychotic drugs companies' market shares, challenges, antipsychotic drugs market drivers, barriers, and trends, and key antipsychotic drugs companies in the market.
  • As per DelveInsight estimates, North America is anticipated to dominate the global antipsychotic drugs market during the forecast period.
  • Furthermore, increased awareness resulted in increased adoption of these drugs in key countries, significantly increasing antipsychotic drugs market growth in key countries.
  • However, the high cost of drug development and launch, addiction caused by antipsychotic drugs, and the stringent regulatory approval process may stall the antipsychotic drugs market growth.

iBio® to Showcase the RubrYc® Discovery Engine During Poster Presentations at Antibody Engineering & Therapeutics Conference 2022

Retrieved on: 
Monday, December 5, 2022
Sequence, Conference, RMIT Platform Technologies Research Institute, Computational biology, Epitope, CCR8, AE, Science, Machine learning, Antibody, Drug development, Agonist, Research, Cancer, Vaccine

BRYAN, Texas, Dec. 05, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, announced today it will present two posters at the Antibody Engineering & Therapeutics Conference 2022 [AE&T] in San Diego, California, December 4-8.

Key Points: 
  • BRYAN, Texas, Dec. 05, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, announced today it will present two posters at the Antibody Engineering & Therapeutics Conference 2022 [AE&T] in San Diego, California, December 4-8.
  • The AE&T Conference features the latest science and research in antibody engineering, design, and selection to drive commercial advances in fields such as immuno-oncology.
  • iBio develops next-generation biopharmaceuticals using computational biology and 3D-modeling of subdominant and conformational epitopes, prospectively enabling the discovery of new antibody treatments for hard-to-target cancers and other diseases.
  • iBio’s mission is to decrease drug failures, shorten drug development timelines, and open up new frontiers against the most promising targets.